Evaluation of phototoxicity induced by the anticancer drug rucaparib

Rucaparib (RCP) is a potent selective inhibitor of both PARP-1 and PARP-2 enzymes that induces synthetic lethality in cancer cells. It is used for the treatment of breast and ovarian tumors harboring deleterious germline or somatic cancer susceptibility genes mutations. Although RCP has an indole ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos-Pujante, Alejandro, Jiménez, María Consuelo, Andreu, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891269/
https://www.ncbi.nlm.nih.gov/pubmed/35236893
http://dx.doi.org/10.1038/s41598-022-07319-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891269/
https://www.ncbi.nlm.nih.gov/pubmed/35236893
http://dx.doi.org/10.1038/s41598-022-07319-9

Ejemplares similares